NCT03328494: Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: All metastatic breast cancer patients are eligible for Part A; Only triple negative breast cancer patients are also eligible for Part B
Exclusions: Uncontrolled or active brain metastases- see trial for details

Comments are closed.

Up ↑